Welcome to our dedicated page for Resverlogix news (Ticker: RVXCF), a resource for investors and traders seeking the latest updates and insights on Resverlogix stock.
Resverlogix Corp. develops epigenetic therapies, with its clinical program centered on apabetalone for cardiovascular disease, associated comorbidities, and post COVID-19 conditions. The company describes apabetalone as a candidate designed to regulate expression of disease-causing genes and restore biological functions altered by chronic illness.
Resverlogix news commonly covers apabetalone research, BETonMACE-related cardiovascular data, clinical and commercial-development partnerships, continuous disclosure status, management cease trade order matters, shareholder meeting results, board composition, and debt or debenture actions.
Resverlogix has rescheduled its Annual and Special Meeting of Shareholders to July 31, 2024, at 1:00 PM MT, from its original date of June 27, 2024. Shareholders will receive a Notice of Meeting and Management Information Circular detailing the matters to be discussed. These documents will also be available on SEDAR+ at www.sedarplus.ca. Following the formal business proceedings, Resverlogix will present a corporate update.
Resverlogix Corp. (TSX: RVX) announced a two-year extension of its US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group. The new maturity date is May 13, 2026.
Along with the extension, Hepalink's conversion privileges have been eliminated, and the interest rate has increased from 12% to 18% per annum, starting May 14, 2024. The changes are subject to execution of definitive transaction documents, customary closing conditions, and Toronto Stock Exchange approval.
CEO Donald McCaffrey expressed appreciation for Hepalink's continued support.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Resverlogix Corp. (RVXCF) announced a shift in focus towards the prevention and treatment of Post COVID-19 Conditions (PCC), commonly referred to as long-COVID. This decision follows feedback from the FDA and highlights the potential of apabetalone to support patients affected by lingering COVID symptoms. The CDC estimates that one in three US adults may experience long-COVID, creating a significant market opportunity. Apabetalone, a first-in-class therapeutic candidate, has a well-established safety profile and is set to enter Phase 3 trials in 2023, with support from EVERSANA™ for global commercialization.